EBS - Emergent BioSolutions Inc Stock Price, Fair Value and News

5.55USD+0.28 (+5.31%)Delayed

Market Summary

USD5.55+0.28

Delayed

5.31%

EBS Stock Price

View Fullscreen

EBS RSI Chart

EBS Valuation

Market Cap

290.8M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

0.25

EV/EBITDA

-1.91

Price/Free Cashflow

-2.2

EBS Price/Sales (Trailing)

EBS Profitability

EBT Margin

-47.09%

Return on Equity

-85.15%

Return on Assets

-31.34%

Free Cashflow Yield

-45.46%

EBS Fundamentals

EBS Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

82.84%

Rev. Growth (Qtr)

8.6%

EBS Earnings

Earnings (TTM)

-565.3M

Earnings Growth (Yr)

104.83%

Earnings Growth (Qtr)

118.18%

Breaking Down EBS Revenue

Last 7 days

27.6%

Last 30 days

192.1%

Last 90 days

255.8%

Trailing 12 Months

-35.8%

How does EBS drawdown profile look like?

EBS Financial Health

Current Ratio

1.08

Debt/Equity

0.67

Debt/Cashflow

-0.19

EBS Investor Care

Shares Dilution (1Y)

3.87%

Diluted EPS (TTM)

-10.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2B	0	0	0
2023	977.0M	1.1B	1.1B	1.0B
2022	1.7B	1.6B	1.5B	1.1B
2021	1.7B	1.7B	1.6B	1.8B
2020	1.1B	1.3B	1.3B	1.6B
2019	855.2M	878.2M	1.0B	1.1B
2018	561.8M	681.2M	705.5M	782.4M
2017	502.7M	512.3M	518.8M	560.9M
2016	540.1M	512.4M	496.9M	488.8M
2015	448.4M	457.1M	477.5M	489.3M
2014	323.5M	351.4M	400.3M	450.1M
2013	274.7M	286.7M	309.2M	312.7M
2012	305.2M	287.4M	295.2M	281.9M
2011	257.9M	283.9M	268.7M	273.4M
2010	0	251.9M	269.0M	286.2M
2009	0	0	0	234.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Emergent BioSolutions Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 07, 2024	hartzel william	sold (taxes)	-1,522	2.29	-665	svp, bioservices
Apr 07, 2024	glessner coleen	sold (taxes)	-1,339	2.29	-585	evp, quality & ethics, and cpl
Mar 05, 2024	hartzel william	sold (taxes)	-1,179	3.41	-346	svp, bioservices
Mar 01, 2024	williams paul anthony	sold (taxes)	-464	3.39	-137	svp, products business
Mar 01, 2024	glessner coleen	sold (taxes)	-1,291	3.39	-381	evp, quality & ethics, and cpl
Mar 01, 2024	lindahl richard s	sold (taxes)	-2,318	3.39	-684	evp, chief financial officer
Mar 01, 2024	fox jennifer lynne	sold (taxes)	-2,383	3.39	-703	evp, ext aff, gc, corp sec
Feb 29, 2024	lindahl richard s	sold (taxes)	-29,189	3.23	-9,037	evp, chief financial officer
Feb 29, 2024	williams paul anthony	sold (taxes)	-1,453	3.23	-450	svp, products business
Feb 29, 2024	fox jennifer lynne	sold (taxes)	-13,252	3.23	-4,103	evp, ext aff, gc, corp sec

Which funds bought or sold EBS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.93	-7,317	13,227	-%
May 16, 2024	Tidal Investments LLC	new	-	33,781	33,781	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-50.13	-281,206	311,635	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-61.04	-1,063,360	741,171	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-57.33	-2,767,370	2,262,220	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-2.41	71,692	2,564,330	0.01%
May 15, 2024	MORGAN STANLEY	added	4.72	308,211	3,273,070	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-6.02	-9,498	1,007,100	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	104	1,370,750	2,602,950	-%
May 15, 2024	BARCLAYS PLC	reduced	-72.63	-239,000	97,000	-%

Are Funds Buying or Selling EBS?

Are funds buying EBS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EBS

No. of Funds

Unveiling Emergent BioSolutions Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.73%	2,974,638	SC 13G/A
Feb 09, 2024	charles schwab investment management inc	5.54%	2,873,984	SC 13G
Jan 23, 2024	state street corp	2.05%	1,062,951	SC 13G/A
Jan 19, 2024	blackrock inc.	18.1%	9,399,197	SC 13G/A
Jan 18, 2024	millennium management llc	4.0%	2,095,662	SC 13G/A
Nov 07, 2023	blackrock inc.	18.1%	9,381,892	SC 13G/A
Oct 10, 2023	state street corp	2.18%	1,131,955	SC 13G/A
Oct 10, 2023	vanguard group inc	5.11%	2,646,366	SC 13G/A
Sep 07, 2023	blackrock inc.	12.4%	6,400,203	SC 13G/A
Sep 07, 2023	millennium management llc	5.2%	2,711,399	SC 13G

Recent SEC filings of Emergent BioSolutions Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading

Peers (Alternatives to Emergent BioSolutions Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Emergent BioSolutions Inc News

Latest updates

Emergent BioSolutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	8.6%	300	277	271	338	164	330	240	243	305	733	286	377	377	583	385	395	193	360	312	243	191
Operating Expenses	-18.5%	261	320	513	631	313	386	285	315	301	438	364	383	248	342	324	269	204	283	241	250	218
S&GA Expenses	-6.0%	85.00	90.00	86.00	91.00	101	93.00	82.00	81.00	85.00	95.00	82.00	91.00	81.00	83.00	76.00	76.00	70.00	72.00	65.00	71.00	65.00
R&D Expenses	-48.7%	15.00	29.00	15.00	26.00	41.00	48.00	42.00	50.00	46.00	38.00	50.00	49.00	53.00	63.00	84.00	48.00	43.00	63.00	53.00	64.00	46.00
EBITDA Margin	41.0%	-0.29*	-0.49*	-0.48*	-0.32*	-0.18*	-0.03*	0.18*	0.19*	0.22*	0.26*	0.28*	0.32*	-	-	-	-	-	-	-	-	-
Interest Expenses	12.0%	24.00	22.00	20.00	29.00	18.00	13.00	9.00	8.00	8.00	9.00	8.00	9.00	9.00	9.00	8.00	6.00	9.00	9.00	10.00	10.00	10.00
Income Taxes	200.0%	3.00	-3.10	-2.50	11.00	22.00	2.00	20.00	-26.40	-0.10	78.00	-12.80	3.00	16.00	71.00	16.00	28.00	-8.80	25.00	16.00	-5.60	-11.80
Earnings Before Taxes	122.3%	12.00	-54.25	-265	-250	-161	-63.30	-67.20	-82.80	-3.80	256	-45.50	7.00	85.00	258	55.00	121	-21.30	71.00	59.00	-15.10	-37.80
EBT Margin	32.4%	-0.47*	-0.70*	-0.67*	-0.51*	-0.38*	-0.19*	0.07*	0.08*	0.13*	0.17*	0.19*	0.24*	-	-	-	-	-	-	-	-	-
Net Income	118.2%	9.00	-49.50	-263	-261	-186	-67.00	-87.10	-52.90	-4.60	193	-40.40	-0.50	67.00	185	40.00	93.00	-12.50	47.00	43.00	-9.50	-26.10
Net Income Margin	34.2%	-0.48*	-0.72*	-0.71*	-0.56*	-0.40*	-0.19*	0.03*	0.06*	0.09*	0.12*	0.13*	0.17*	-	-	-	-	-	-	-	-	-
Free Cashflow	-454.6%	-73.40	21.00	47.00	-126	-199	69.00	-101	-47.70	-69.50	282	-38.50	-96.70	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.1%	1,804	1,823	1,893	2,179	2,950	3,166	2,896	2,735	2,780	2,958	2,868	2,915	2,900	2,883	2,616	2,466	2,279	2,327	2,334	2,321	2,154
Current Assets	0.4%	682	680	721	778	1,221	1,210	1,098	1,084	1,100	1,270	1,112	1,162	1,181	1,196	959	796	627	686	700	693	529
Cash Equivalents	-29.3%	79.00	112	88.00	89.00	430	643	241	358	436	576	404	448	548	622	415	269	182	168	139	178	137
Inventory	1.4%	333	329	354	354	368	351	528	426	401	345	365	386	407	307	270	236	248	223	230	232	211
Net PPE	-0.9%	379	383	395	396	717	818	807	798	808	800	769	744	693	644	607	580	549	542	529	521	513
Goodwill	-	-	-	-	218	218	218	225	225	225	225	267	267	267	267	267	266	266	267	269	268	268
Liabilities	-2.9%	1,140	1,174	1,196	1,223	1,747	1,779	1,463	1,222	1,205	1,346	1,345	1,372	1,377	1,436	1,365	1,267	1,204	1,239	1,299	1,332	1,166
Current Liabilities	-3.2%	630	651	664	693	1,216	1,229	264	277	249	374	365	378	370	385	299	294	207	216	275	301	248
Long Term Debt	0.0%	447	447	448	448	448	449	1,032	794	802	809	817	825	833	841	849	758	763	798	813	830	732
LT Debt, Current	11.0%	459	414	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	10.00	10.00
LT Debt, Non Current	-100.0%	-	447	448	448	448	449	1,032	794	802	809	817	825	833	841	849	758	763	798	813	830	732
Shareholder's Equity	2.2%	664	649	697	958	1,204	1,388	1,433	1,508	1,567	1,612	1,523	1,544	1,523	1,451	1,252	1,199	1,075	1,091	1,035	989	987
Retained Earnings	41.3%	-12.80	-21.80	28.00	290	551	739	806	898	954	950	769	801	797	727	542	502	409	422	375	332	341
Additional Paid-In Capital	0.6%	910	904	900	896	878	874	860	849	835	829	817	804	790	785	771	759	726	716	709	702	690
Shares Outstanding	0.4%	52.00	52.00	52.00	52.00	50.00	50.00	50.00	50.00	51.00	54.00	54.00	54.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	381	-	-	-	1,500	-	-	-	3,400	-	-	-	4,200	-	-	-	2,500	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-295.0%	-62.60	32.00	60.00	-114	-184	93.00	-74.00	-15.60	-37.30	328	17.00	-29.70	5.00	246	105	128	58.00	122	-3.10	-35.80	105
Share Based Compensation	47.5%	6.00	4.00	4.00	8.00	7.00	12.00	11.00	12.00	10.00	10.00	10.00	11.00	11.00	11.00	10.00	24.00	7.00	6.00	6.00	8.00	7.00
Cashflow From Investing	5.3%	-10.80	-11.40	-18.90	258	-15.10	-45.40	-271	-32.10	-32.20	-45.80	-55.20	-67.00	-56.10	-36.90	-45.70	-45.10	-24.20	-36.10	-15.30	-24.10	-21.40
Cashflow From Financing	766.0%	41.00	5.00	-43.00	-486	-10.50	353	229	-30.70	-70.50	-110	-5.00	-3.80	-22.20	-2.30	87.00	5.00	-20.00	-57.90	-19.70	100	-58.40
Buy Backs	-	-	-	-	-	-	-	-	23.00	52.00	106	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EBS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Total revenues	$ 300.4	$ 164.3
Operating expenses:
Cost of goods and services sold	144.6	152.9
Research and development	15.1	40.7
Selling, general and administrative	84.7	101.3
Amortization of intangible assets	16.2	17.0
Total operating expenses	260.6	311.9
Income (loss) from operations	39.8	(147.6)
Other income (expense):
Interest expense	(24.3)	(17.9)
Other, net	(3.4)	4.9
Total other income (expense), net	(27.7)	(13.0)
Income (loss) before income taxes	12.1	(160.6)
Income tax provision	3.1	25.6
Net income (loss)	$ 9.0	$ (186.2)
Earnings Per Share, Diluted [Abstract]
Basic (in dollars per share)	$ 0.17	$ (3.71)
Diluted (in dollars per share)	$ 0.17	$ (3.71)
Weighted average shares outstanding
Basic (in shares)	52.2	50.2
Diluted (in shares)	52.2	50.2
Total Product sales, net
Revenues [Abstract]
Product sales	$ 273.9	$ 143.4
Commercial Product sales
Revenues [Abstract]
Product sales	118.5	106.2
Operating expenses:
Cost of goods and services sold	52.1	45.8
MCM Product sales
Revenues [Abstract]
Product sales	155.4	37.2
Operating expenses:
Cost of goods and services sold	62.2	55.4
Total Bioservices revenues
Revenues [Abstract]
Total Bioservices revenues	18.5	14.4
Operating expenses:
Cost of goods and services sold	30.3	51.7
Services
Revenues [Abstract]
Product sales	18.3	12.6
Leases
Revenues [Abstract]
Leases	0.2	1.8
Contracts and grants
Revenues [Abstract]
Product sales	$ 8.0	$ 6.5

EBS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 78.5	$ 111.7
Restricted cash	0.5	0.0
Accounts receivable, net	233.5	191.0
Inventories, net	333.4	328.9
Prepaid expenses and other current assets	36.5	47.9
Total current assets	682.4	679.5
Property, plant and equipment, net	379.4	382.8
Intangible assets, net	550.4	566.6
Other assets	191.4	194.3
Total assets	1,803.6	1,823.2
Current liabilities:
Accounts payable	100.2	112.2
Accrued expenses	14.3	18.6
Accrued compensation	42.0	74.1
Debt, current portion	459.2	413.7
Other current liabilities	14.5	32.7
Total current liabilities	630.2	651.3
Debt, net of current portion	446.7	446.5
Deferred tax liability	34.8	47.2
Other liabilities	28.0	28.9
Total liabilities	1,139.7	1,173.9
Stockholders' equity:
Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding	0.0	0.0
Common stock, $0.001 par value per share; 200.0 shares authorized, 58.0 and 57.8 shares issued; 52.4 and 52.2 shares outstanding, respectively	0.1	0.1
Treasury stock, at cost, 5.6 and 5.6 common shares, respectively	(227.7)	(227.7)
Additional paid-in capital	909.8	904.4
Accumulated other comprehensive loss, net	(5.5)	(5.7)
Accumulated deficit	(12.8)	(21.8)
Total stockholders’ equity	663.9	649.3
Total liabilities and stockholders’ equity	$ 1,803.6	$ 1,823.2

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

WEBSITE	emergentbiosolutions.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2500

Emergent BioSolutions Inc Frequently Asked Questions

What is the ticker symbol for Emergent BioSolutions Inc? What does EBS stand for in stocks?

EBS is the stock ticker symbol of Emergent BioSolutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Emergent BioSolutions Inc (EBS)?

As of Fri May 17 2024, market cap of Emergent BioSolutions Inc is 290.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EBS stock?

You can check EBS's fair value in chart for subscribers.

What is the fair value of EBS stock?

You can check EBS's fair value in chart for subscribers. The fair value of Emergent BioSolutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Emergent BioSolutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EBS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Emergent BioSolutions Inc a good stock to buy?

The fair value guage provides a quick view whether EBS is over valued or under valued. Whether Emergent BioSolutions Inc is cheap or expensive depends on the assumptions which impact Emergent BioSolutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EBS.

What is Emergent BioSolutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EBS's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 0.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EBS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Emergent BioSolutions Inc's stock?

In the past 10 years, Emergent BioSolutions Inc has provided -0.122 (multiply by 100 for percentage) rate of return.